

Ca²⁺ influx evoked by inositol-3,4,5,6-tetrakisphosphate in *ras*-transformed NIH/3T3 fibroblasts

Minako Hashii^{a,**}, Masato Hirata^b, Shoichiro Ozaki^c, Yoshinori Nozawa^d, Haruhiro Higashida^{a,*}

^aDepartment of Biophysics, Neuroinformation Research Institute, Kanazawa University School of Medicine, 13-1 Takara-machi, Kanazawa 920, Japan

^bDepartment of Biochemistry, Faculty of Dentistry, Kyushu University, Fukuoka 812, Japan

^cDepartment of Applied Chemistry, Faculty of Engineering, Ehime University, Matsuyama 790, Japan

^dDepartment of Biochemistry, Gifu University School of Medicine, Gifu 500, Japan

Received 6 January 1994; revised version received 4 February 1994

Abstract

Infusion of inositol-3,4,5,6-tetrakisphosphate (Ins(3,4,5,6)P₄) from the patch pipette into the cytoplasm, produced a biphasic intracellular free Ca²⁺ concentration ([Ca²⁺]_i) increase in *ras*-transformed NIH/3T3 (DT) cells. The Ins(3,4,5,6)P₄-induced increase in DT cells depended upon extracellular Ca²⁺, and was enhanced by membrane hyperpolarization. Identical [Ca²⁺]_i increases were observed with intracellular application of inositol-1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P₄) and inositol-1,3,4,6-tetrakisphosphate but not with inositol-1,2,4,5-tetrakisphosphate, inositol-1,4,5-trisphosphate or inositol-1,3,4,5,6-pentakisphosphate. Stimulation of DT cells with bradykinin increased the levels of Ins(3,4,5,6)P₄ and Ins(1,3,4,5)P₄. These results suggest that Ins(3,4,5,6)P₄ may serve as a second messenger for continuous Ca²⁺ influx along with other tetrakisphosphates downstream from bradykinin receptors in DT cells.

Key words: Receptor operated Ca²⁺ influx; Intracellular Ca²⁺ concentration; Inositol polyphosphate; Second messenger; Mouse fibroblast

1. Introduction

Inositol tetrakisphosphates are formed after stimulation of receptors for hormones and neurotransmitters in mammalian cells. Inositol-1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P₄) is produced by phosphorylation of inositol-1,4,5-trisphosphate (Ins(1,4,5)P₃) after application of agonist [1,2]. Ins(1,3,4,5)P₄ serves as a source inositol phosphate for producing inositol-1,3,4,5,6-pentakisphosphate (Ins(1,3,4,5,6)P₅) via inositol-1,3,4-trisphosphate [3,4]. Recently it has been shown that agonists can increase the level of inositol-3,4,5,6-tetrakisphosphate (Ins(3,4,5,6)P₄) [5–9], from which one pathway of

formation is dephosphorylation of Ins(1,3,4,5,6)P₅ from the abundant precursor pool of the cell membrane [9,10]. However, the functional role of Ins(3,4,5,6)P₄ is not known [10].

Here we report the effect of intracellular application of Ins(3,4,5,6)P₄ on intracellular free Ca²⁺ concentration ([Ca²⁺]_i) in fura-2 loaded mouse fibroblasts under voltage-clamp conditions. To characterize the mechanism of the Ca²⁺ influx produced by Ins(3,4,5,6)P₄ in mouse fibroblasts, we used Ki-*ras*-transformed NIH/3T3 fibroblast cells, in which we have demonstrated Ca²⁺ influx induced by Ins(1,3,4,5)P₄ [11]. Furthermore, we measured the Ins(3,4,5,6)P₄ as well as Ins(1,3,4,5)P₄ levels in *ras*-transformed fibroblasts stimulated with bradykinin in order to address the question of whether inositol tetrakisphosphates can be second messengers for bradykinin-induced Ca²⁺ influx in the cells.

2. Materials and methods

2.1 Cell culture

v-Ki-*ras*-transformed NIH/3T3 fibroblasts (DT cells) [11] were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum. Cells were plated at a density of 1–1.5 × 10⁵ cells/mm² on a fluorescence-free glass coverslip attached to a silicone tube (1.5-cm diameter and 0.9-cm height) with silicone sealant and cultured for 2 days at 37°C.

*Corresponding author. Fax: (81) (762) 62 1783.

**Present address: Department of Cortical Function Disorder, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187, Japan.

Abbreviations: Ins(1,3,4,5)P₄, inositol-1,3,4,5-tetrakisphosphate; Ins(1,4,5)P₃, inositol-1,4,5-trisphosphate; Ins(1,3,4,5,6)P₅, inositol-1,3,4,5,6-pentakisphosphate; Ins(3,4,5,6)P₄, inositol-3,4,5,6-tetrakisphosphate; [Ca²⁺]_i, intracellular free Ca²⁺ concentration; DMEM, Dulbecco's modified Eagle's medium; Ins(1,3,4,6)P₄, inositol-1,3,4,6-tetrakisphosphate; Ins(1,2,4,5)P₄, inositol-1,2,4,5-tetrakisphosphate; [Ca²⁺]_o, extracellular Ca²⁺ concentration.

2.2. $[Ca^{2+}]_i$ measurement

Microspectrofluorometric determination of $[Ca^{2+}]_i$ with fura-2 was performed in DT cells, as described previously [11,12]. Briefly, they were loaded with 5 μ M fura-2 acetoxymethylester (Dojindo Laboratories, Kumamoto, Japan) for 45 min at 37°C. Fluorescence was measured at 35°C at a determined site through a pin hole (10–20 μ m) with alternating excitation wavelengths of 340 and 380 nm, using a Ca^{2+} microspectrometric system (model OSP-3, Olympus Optical Co., Tokyo).

2.3. Patch clamp and intracellular application

Patch voltage-clamp on fura-2-loaded cells was performed in the whole-cell configuration with a patch electrode [13], as described previously [11]. DT cells were superfused at 35°C with Docherty's Ca^{2+} solution [14] of the following composition (in mM), slightly modified from the original recipe: $CaCl_2$, 2; tetraethylammonium chloride, 100; CsCl, 5; $MgCl_2$, 1; glucose, 25; HEPES, 25, pH 7.3 (buffered by about 7.5 mM CsOH). Ca^{2+} -free solution was prepared by omitting $CaCl_2$ and adding 0.1 mM EGTA to the solution. Patch electrodes contained solution of the following composition (in mM): CsCl, 150; $MgCl_2$, 1; Na_2ATP , 1; fura-2, 0.1; HEPES, 10, pH 7.2, buffered with CsOH. The resistance of electrodes filled with the solution was 8–16 M Ω . About 90 s after the initial touch, the electrode tip was sealed to the cell body by suction (seal resistance, >1 G Ω), and the membrane patch under the electrode tip was broken by further suction. After successfully establishing the whole-cell recording mode the cell was voltage-clamped.

Inositol polyphosphates (10 μ M) dissolved in intracellular recording medium in the patch pipettes were applied by diffusion into the cytoplasm after rupture of the membrane patch to establish whole-cell mode.

2.4. Inositol tetrakisphosphate measurement

Cells were cultured in inositol-free DMEM supplemented with 10% fetal calf serum. They were labeled with [3H]inositol (7.7 μ Ci/ml, myo[3H]inositol, 19.8 GBq/mg (535 mCi/mg), Amersham, UK) for 96 h. All experiments were carried out at 37°C. At the end of the labeling protocols, the culture medium was aspirated, and cells were incubated for 20 min in HEPES-DMEM (pH 7.4). [3H]inositol phosphate formation was initiated by replacing the preincubation buffer with fresh HEPES-DMEM containing 1 μ M bradykinin, and incubation was continued for 0–10 min. The reaction was stopped by adding to each well 50 μ l of ice-cold 100% trichloroacetic acid (final concentration 4.8%). After centrifugation, the supernatant was neutralized by adding 1 N NaOH, and treated with water-saturated diethylether (3 ml \times 3). The [3H]inositol tetrakisphosphates in the samples were separated on a Pertisphere Wax column (Whatman, Maidstone, UK), according to the method of Wong et al. [15].

2.5. Drugs

Ins(1,4,5)P₃ and inositol-3-monophosphate (Ins(3)P₁) were purchased from Dojindo Laboratories. Ins(3,4,5,6)P₄ [16], Ins(1,3,4,5)P₄ [17] and inositol-1,3,4,6-tetrakisphosphate (Ins(1,3,4,6)P₄) [18] were synthesized according to the methods described by Watanabe et al. Inositol-1,2,4,5-tetrakisphosphate (Ins(1,2,4,5)P₄) was synthesized by the method described elsewhere by one of the authors (M.H.).

3. Results and discussion

Application of 10 μ M Ins(3,4,5,6)P₄ through a patch pipette in *ras*-transformed NIH/3T3 (DT) cells held at –40 mV resulted in an initial elevation of $[Ca^{2+}]_i$, followed by a sustained increase, in the presence of extracellular Ca^{2+} ($n = 7$) (Fig. 1A-a and B and Table 1), with the ED₅₀ of about 8 μ M. Elevation of $[Ca^{2+}]_i$ was completely abolished in zero extracellular Ca^{2+} ($[Ca^{2+}]_o$) ($n = 8$) (Fig. 1A-b), and the elevation was recovered by restoration of external Ca^{2+} . On the contrary, the $[Ca^{2+}]_i$ rise evoked by injection of Ins(1,4,5)P₃ into the cyto-

plasm of DT cells was transient and was observed even in the absence of extracellular Ca^{2+} (Fig. 1B and Table 1). The results show that the source of Ca^{2+} for the Ins(3,4,5,6)P₄-induced $[Ca^{2+}]_i$ increase is extracellular in both the initial and sustained phases and for Ins(1,4,5)P₃ is largely due to mobilization of Ca^{2+} from intracellular stores [2] in DT cells.

As shown in Fig. 2A, Ins(3,4,5,6)P₄-evoked $[Ca^{2+}]_i$ increased as the membrane potential was hyperpolarized in DT cells. $[Ca^{2+}]_i$ in both the initial and late phases following injection of Ins(3,4,5,6)P₄ increased significantly as the membrane potential hyperpolarized below –15 or –40 mV, respectively (Fig. 2B), probably because of increased electrochemical driving forces [11]. Membrane hyperpolarization itself caused little or no increase of $[Ca^{2+}]_i$ as shown in inositol phosphate-free cells (Fig. 2C). A similar hyperpolarization-enhanced Ca^{2+} influx has been reported in oocytes expressing muscarinic sub-type m3 receptors [19].

The specificity of the action of Ins(3,4,5,6)P₄ on Ca^{2+} influx was examined by applying other inositol tetrakisphosphate isomers in DT cells (Table 1). Ins(1,3,4,5)P₄ and Ins(1,3,4,6)P₄ (10 μ M in pipettes) produced similar biphasic $[Ca^{2+}]_i$ elevations in the presence of external Ca^{2+} , as for Ins(3,4,5,6)P₄, and complete suppression was observed in the absence of external Ca^{2+} . Interestingly, Ins(1,2,4,5)P₄, a nonbiological synthetic inositol tetrakisphosphate, resulted in transient but extracellular Ca^{2+} -dependent Ca^{2+} influx, as produced by the three naturally occurring inositol tetrakisphosphates. Ins(1,3,4,5,6)P₅, Ins(3)P₁ and GDP- β -S had no ability for Ca^{2+} mobilization and Ca^{2+} influx. GTP- γ -S reproduced

Table 1
Effect of 10 μ M inositol phosphates, 100 μ M GTP- γ -S and 100 μ M GDP- β -S on $[Ca^{2+}]_i$ elevation in DT cells

Compounds included in pipettes	DT cells		
	2 mM $[Ca^{2+}]_o$		0 mM $[Ca^{2+}]_o$
	Initial peak	at 10 min	at 1 min
None	115 \pm 3 (7)	116 \pm 5 (7)	102 \pm 3 (5)
Ins(3)P ₁	136 \pm 11 (6)	117 \pm 5 (5)	105 \pm 1 (5)
Ins(1,4,5)P ₃	211 \pm 15 (6)**	113 \pm 8 (6)	222 \pm 15 (5)**
Ins(1,3,4,5)P ₄	430 \pm 70 (6)**	188 \pm 22 (6)*	103 \pm 1 (5)
Ins(1,3,4,6)P ₄	441 \pm 72 (8)**	182 \pm 17 (5)*	100 \pm 0 (5)
Ins(3,4,5,6)P ₄	334 \pm 29 (8)**	171 \pm 14 (7)*	103 \pm 1 (8)
(3,4,5,6)P ₄ + (1,4,5)P ₃	387 \pm 40 (7)**	199 \pm 23 (7)*	241 \pm 41 (5)*
Ins(1,2,4,5)P ₄	208 \pm 23 (7)**	92 \pm 6 (4)	107 \pm 4 (8)
Ins(1,3,4,5,6)P ₅	123 \pm 16 (4)	100 \pm 4 (4)	103 \pm 4 (6)
GTP- γ -S	261 \pm 40 (6)*	114 \pm 4 (4)	215 \pm 27 (7)**
GDP- β -S	117 \pm 6 (6)	122 \pm 13 (5)	103 \pm 1 (5)

Data are shown as mean \pm S.E.M. of the $[Ca^{2+}]_i$ level, represented as the percentage of the value of $[Ca^{2+}]_i$ just before membrane breaking. Number of experiments are shown in parentheses. * and **, significantly different from values in isomer-free DT cells, $P < 0.05$ and 0.01, respectively.




Fig. 1. Effect of extracellular Ca^{2+} on the $[Ca^{2+}]_i$ elevation induced by intracellular application of Ins(3,4,5,6) P_4 or Ins(1,4,5) P_3 in DT cells. (A) $[Ca^{2+}]_i$ was measured in DT cells in the presence of 2 mM extracellular Ca^{2+} (a) or in zero extracellular Ca^{2+} with 0.1 mM EGTA (b). Changes in $[Ca^{2+}]_i$ were recorded under voltage-clamp with patch pipettes filled with 10 μ M Ins(3,4,5,6) P_4 . Ins(3,4,5,6) P_4 was loaded into cells by diffusion from the pipettes after breaking the membrane at the time indicated by arrows. In (b), $[Ca^{2+}]_o$ concentration was raised to 2 mM from about 4 min after injection, indicated by thick bars. The holding membrane potential was -40 mV. (B) Plots of time course of $[Ca^{2+}]_i$ change produced by intracellular application of Ins(3,4,5,6) P_4 or Ins(1,4,5) P_3 in DT cells. $[Ca^{2+}]_i$ levels are represented as % of the value of $[Ca^{2+}]_i$ just before membrane rupture. Points show mean values in response to 10 μ M Ins(3,4,5,6) P_4 (●, ○), 10 μ M Ins(1,4,5) P_3 (▲, △), and isomer-free control solution (■, □), in the presence (filled symbols) or absence (open symbols) of 2 mM extracellular Ca^{2+} , respectively. Bars indicate S. E. M. Numbers of experiments are 5–7. * and **, significantly different from the values at the same time point in isomer-free cells, $P < 0.05$ and 0.01 , respectively.

the effect of Ins(1,4,5) P_3 , not that of the inositol tetrakisphosphate. Use of Ins(3,4,5,6) P_4 in combination with Ins(1,4,5) P_3 had little or no additive effect, suggesting that Ca^{2+} influx is strictly specific to Ins(3,4,5,6) P_4 in DT cells.

DT cells [11] or *Xenopus* oocytes with m3-muscarinic acetylcholine receptors expressed [19] possess a Ca^{2+} influx pathway that becomes prominent by membrane hyperpolarization. Interestingly, application of bradykinin to the *ras*-transformed cells [11] or of acetylcholine to the oocytes [19] evokes repetitive transient increases of Ca^{2+} , or cytosolic Ca^{2+} oscillations. Ca^{2+} oscillations in these preparations have been reported to occur in an extracellular Ca^{2+} dependent-manner and to be enhanced by hyperpolarization [11,19]. This suggests that Ca^{2+} influx across the plasma membrane is necessary for maintenance of agonist-induced Ca^{2+} oscillations. Therefore, we measured the Ins(3,4,5,6) P_4 and Ins(1,3,4,5) P_4 levels

in *ras*-transformed fibroblasts stimulated with bradykinin.

The pre-stimulating control level of Ins(1,3,4,5) P_4 and Ins(3,4,5,6) P_4 was 768 ± 18 dpm (mean \pm S.E.M., $n = 4$) and 131 ± 24 dpm ($n = 4$) in DT cells, respectively. Bradykinin stimulation increased the level of radioactivity in $[^3H]$ Ins(1,3,4,5) P_4 by 2.6- to 3.1-fold and $[^3H]$ Ins(3,4,5,6) P_4 by 2.8- to 5.0-fold (Fig. 3). $[^3H]$ Ins(1,3,4,5) P_4 levels increased rapidly, while $[^3H]$ Ins(3,4,5,6) P_4 levels increased slowly, appearing to reach a plateau after 5 min following receptor activation. The maximal peak level was 2359 ± 616 dpm ($n = 3$) at 1 min for $[^3H]$ Ins(1,3,4,5) P_4 and 658 ± 180 dpm ($n = 3$) at 5 min for $[^3H]$ Ins(3,4,5,6) P_4 , respectively. A similar long-lasting increase of the Ins(3,4,5,6) P_4 level has been reported in response to stimulation by angiotensin II in adrenal glomerulosa cells [5], fMLP in HL-60 myeloid cells [6], bombesin in AR4-2J pancreatoma cells [7], and




Fig. 2. Relationship between $[Ca^{2+}]_i$ and membrane potential in DT cells with or without $Ins(3,4,5,6)P_4$ injected. (A) Time course of $[Ca^{2+}]_i$ in voltage-clamped DT cells at three different holding potentials. The membrane potential is shown at the left. $10 \mu M$ $Ins(3,4,5,6)P_4$ was infused into the cells at the time indicated by the arrow, as described in Fig. 1. Plots of $[Ca^{2+}]_i$ as a function of membrane potential in the presence (B) or absence (C) of $10 \mu M$ $Ins(3,4,5,6)P_4$ in the pipettes. $[Ca^{2+}]_i$ level is represented as % of the value of $[Ca^{2+}]_i$ just before membrane rupture. Each point shows the mean, and bars indicate S.E.M. Numbers of experiments are 5–8. Symbols indicate $[Ca^{2+}]_i$ immediately after injection (●) and after 10 min (○). * and **, significantly different from values at the identical membrane potential in isomer-free DT cells as indicated in C, $P < 0.05$ and 0.01 , respectively.

vasopressin in WRK-1 rat mammary tumor cells [8]. Together, these results show that $Ins(3,4,5,6)P_4$ is a second messenger in a variety of cells but not specifically in *ras*-transformed cells.

In the present experiment, intracellular injection of the three inositol tetrakisphosphates, $Ins(3,4,5,6)P_4$, $Ins(1,3,4,5)P_4$, $Ins(1,3,4,6)P_4$, mimicked the bradykinin-induced increases of $[Ca^{2+}]_i$ due to Ca^{2+} influx in *ras*-transformed fibroblasts, with little or no specificity between the three, but with a clear different action from those of $Ins(1,4,5)P_3$, $Ins(1,2,4,5)P_4$, and $Ins(1,3,4,5,6)P_5$. In DT cells, $Ins(1,3,4,5)P_4$ [11] and $Ins(3,4,5,6)P_4$ do not require the simultaneous injection with $Ins(1,4,5)P_3$ in order to stimulate Ca^{2+} entry, as was reported previously [20], suggesting that these compounds alone can elicit Ca^{2+} influx. Recently, it has been shown that there are receptors for $Ins(1,3,4,5)P_4$ which are Ca^{2+} -permeable channels in the plasma membrane [20–22]. Our results suggest that inositol tetrakisphosphate receptors and/or Ca^{2+} -permeable channels may have a non-selective sensitivity for the naturally occurring tetrakisphosphates tested.

As shown in Fig. 1A, the $[Ca^{2+}]_i$ increase evoked by $Ins(3,4,5,6)P_4$ in pipettes both in the presence of external Ca^{2+} and after Ca^{2+} restoration decayed to result in the biphasic. Since fresh $Ins(3,4,5,6)P_4$ can be supplied through the pipettes, this decay may not be due to degradation of $Ins(3,4,5,6)P_4$, but to negative feedback or

desensitization of $Ins(3,4,5,6)P_4$ receptors to inactivate Ca^{2+} influx.

Three pathways which lead to accumulation of $Ins(3,4,5,6)P_4$ are known: (i) dephosphorylation by 1-phosphatase action on $Ins(1,3,4,5,6)P_5$ [5,7,9]; (ii) inhibition of $Ins(3,4,5,6)P_4$ -1-kinase [10]; or (iii) isomerase action on inositol-1,4,5,6-tetrakisphosphate [9]. Which-ever route is taken transformed NIH/3T3 cells, the level of $Ins(3,4,5,6)P_4$ was slowly increased in response to bradykinin. Although $Ins(1,3,4,5)P_4$ formation was much larger than that of $Ins(3,4,5,6)P_4$ in *ras*-transformed cells, the findings suggest that $Ins(3,4,5,6)P_4$ is a second messenger downstream from bradykinin receptor stimulation, specially in the late phase.

As a preliminary result, we have observed that application of $Ins(3,4,5,6)P_4$ into parental 'untransformed' NIH/3T3 fibroblast cells produces an initial elevation of $[Ca^{2+}]_i$ but no sustained elevation. The difference in response between control and *ras*-transformed cells seems not to lie in a quantitative difference in $Ins(3,4,5,6)P_4$ formation but in a mechanism whereby $Ins(3,4,5,6)P_4$ -induced Ca^{2+} influx is maintained at a higher level in *ras*-transformed cells. The important question arises as to why $Ins(3,4,5,6)P_4$ injection produces only a Ca^{2+} plateau rather than mimics cytosolic Ca^{2+} oscillations in *ras*-transformed cells. The reason may reside on no activation of Ca^{2+} pumps which may not be induced by injection of $Ins(3,4,5,6)P_4$, whereas application of bradykinin




Fig. 3. Changes in the level of [³H]-labelled Ins(1,3,4,5)P₄ and Ins(3,4,5,6)P₄ in DT cells in response to bradykinin. Cells were labelled to equilibrium with [³H] inositol and then stimulated with 1 μ M bradykinin for the periods indicated. Inositol tetrakisphosphates were extracted and separated by high pressure liquid chromatography on Partisphere-WAX columns and their radioactivities were determined. Each point shows the mean of levels of [³H]Ins(1,3,4,5)P₄ (■) and [³H]Ins(3,4,5,6)P₄ (●) at the indicated time points. Bars indicate S.E.M. Numbers of experiments are 3–6.

may be able to do, as pointed out previously [11]. In summary, Ins(3,4,5,6)P₄ in concert with other tetrakisphosphates may play an important role in producing Ca²⁺ influx to maintain the [Ca²⁺]_i at a certain level during cytosolic Ca²⁺ oscillations following agonist-stimulation in *ras*-transformed fibroblast cells.

Acknowledgements: We thank H. Robinson for a critical reading of the manuscript.

References

- [1] Irvine, R.F., Letcher, A.J., Heslop, J.P. and Berridge, M.J. (1986) *Nature* 320, 631–634.
- [2] Berridge, M.J. and Irvine, R.F. (1989) *Nature* 341, 197–205.
- [3] Stephens, L.R., Hawkins, P.T., Barker, C.J. and Downes, C.P. (1988) *Biochem. J.* 253, 721–733.
- [4] Shears, S.B. (1989) *J. Biol. Chem.* 264, 19879–19886.
- [5] Balla, T., Baukal, A.J., Hunyady, L. and Catt, K.J. (1989) *J. Biol. Chem.* 264, 13605–13611.
- [6] Pittet, D., Schlegel, W., Lew, D.P., Monod, A. and Mayr, G.W. (1989) *J. Biol. Chem.* 264, 18489–18493.
- [7] Menniti, F.S., Oliver, K.G., Nogimori, K., Obie, J.F., Shears, S.B. and Putney, J.W., Jr. (1990) *J. Biol. Chem.* 265, 11167–11176.
- [8] Barker, C.J., Wong, N.S., Maccallum, S.M., Hunt, P.A., Michell, R.H. and Kirk, C.J. (1992) *Biochem. J.* 286, 469–474.
- [9] Oliver, K.G., Putney, J.W., Jr., Obie, J.F. and Shears, S.B. (1992) *J. Biol. Chem.* 267, 21528–21534.
- [10] Menniti, F.S., Oliver, K.G., Putney, J.W., Jr. and Shears, S.B. (1993) *Trends Biochem. Sci.* 18, 53–56.
- [11] Hashii, M., Nozawa, Y. and Higashida, H. (1993) *J. Biol. Chem.* 268, 19403–19410.
- [12] Ogura, A., Myojo, Y. and Higashida, H. (1990) *J. Biol. Chem.* 265, 3577–3584.
- [13] Penner, R., Matthews, G. and Neher, E. (1988) *Nature* 334, 499–504.
- [14] Docherty, R.J. (1988) *J. Physiol.* 398, 33–47.
- [15] Wong, N.S., Barker, C.J., Morris, A.J., Craxton, A., Kirk, C.J. and Michell, R.H. (1992) *Biochem. J.* 286, 459–468.
- [16] Watanabe, Y., Nakahira, H., Bunya, M. and Ozaki, S. (1987) *Tetrahedron Lett.* 28, 4179–4180.
- [17] Watanabe, Y., Fujimoto, T., Shinohara, T. and Ozaki, S. (1991) *J. Chem. Soc. Chem. Commun.* 1991, 428–429.
- [18] Watanabe, Y., Mitani, M., Morita, T. and Ozaki, S. (1989) *J. Chem. Soc. Chem. Commun.* 1989, 482–483.
- [19] Girard, S. and Clapham, D. (1993) *Science* 260, 229–232.
- [20] Lückhoff, A. and Clapham, D.E. (1992) *Nature* 355, 356–358.
- [21] Irvine, R.F. (1992) *FASEB J.* 6, 3085–3091.
- [22] Neher, E. (1992) *Nature* 355, 298–299.